Verquvo

Vericiguat

Reduce risk of CV death & heart failure (HF) hospitalization following worsening HF event, in adults w/ symptomatic chronic HF & ejection fraction <45%, in combination w/ other HF therapies.

Initially 2.5 mg once daily. Double the dose approx every 2 wk to reach target maintenance dose of 10 mg once daily, as tolerated by the patient.

Should be taken with food: For patients w/ difficulty swallowing, tab may be crushed & mixed w/ water immediately before administration.

Concomitant use of other soluble guanylate cyclase (sGC) stimulators eg, riociguat.

May cause symptomatic hypotension. Patients w/ systolic BP <100 mmHg or symptomatic hypotension at treatment initiation. Potential for symptomatic hypotension in patients w/ hypovolemia, severe left ventricular outflow obstruction, resting hypotension, autonomic dysfunction, history of hypotension, or concomitant treatment w/ antihypertensives or organic nitrates. Adjust dose of diuretics & treat other causes of hypotension (eg, hypovolemia) if symptomatic hypotension occurs; then reduce dose or interrupt treatment temporarily if symptomatic hypotension persists despite such measures. Not recommended w/ phosphodiesterase-5 (PDE-5) inhibitors eg, sildenafil in patients w/ heart failure due to potential increased risk for symptomatic hypotension. Not recommended in patients w/ eGFR <15 mL/min/1.73 m² at treatment initiation or on dialysis; severe hepatic impairment. Not recommended during pregnancy & in women of childbearing potential not using contraception. Lactation. Ped patients <18 yr.

Anemia; nausea, dyspepsia, vomiting, GERD; dizziness, headache; hypotension.

Potential increased risk for symptomatic hypotension w/ PDE-5 inhibitors eg, sildenafil. Concomitant use of other sGC stimulators eg, riociguat.

Other Cardiovascular Drugs

C01DX22 - vericiguat ; Belongs to the class of other vasodilators used in cardiac diseases.

Rx